Interchange Capital Partners LLC Buys 5,432 Shares of Merck & Co., Inc. $MRK

Interchange Capital Partners LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 51.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,005 shares of the company’s stock after purchasing an additional 5,432 shares during the period. Interchange Capital Partners LLC’s holdings in Merck & Co., Inc. were worth $2,057,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. D.A. Davidson & CO. raised its stake in Merck & Co., Inc. by 4.4% in the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock valued at $60,731,000 after acquiring an additional 24,576 shares during the period. Farther Finance Advisors LLC boosted its position in Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after purchasing an additional 32,114 shares during the period. Pinnbrook Capital Management LP boosted its position in Merck & Co., Inc. by 95.2% during the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock worth $2,450,000 after purchasing an additional 11,355 shares during the period. Cibc World Market Inc. increased its stake in shares of Merck & Co., Inc. by 32.6% in the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after purchasing an additional 320,143 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its stake in shares of Merck & Co., Inc. by 13.9% in the fourth quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock worth $193,999,000 after purchasing an additional 224,752 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
• Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
• Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
• Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
• Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
• Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Wells Fargo & Company lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Citigroup initiated coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Finally, Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday. Fifteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $135.50.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $135.57 on Friday. The firm’s 50 day simple moving average is $125.25 and its 200 day simple moving average is $119.83. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $334.49 billion, a PE ratio of 108.46, a price-to-earnings-growth ratio of 5.73 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.68.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares in the company, valued at $4,942,755. This represents a 21.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last ninety days. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.